Aytu BioPharma Balance Sheet Health
Financial Health criteria checks 3/6
Aytu BioPharma has a total shareholder equity of $45.8M and total debt of $21.9M, which brings its debt-to-equity ratio to 47.8%. Its total assets and total liabilities are $141.4M and $95.6M respectively.
Key information
47.8%
Debt to equity ratio
US$21.92m
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.50m |
| Equity | US$45.82m |
| Total liabilities | US$95.62m |
| Total assets | US$141.44m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AY20's short term assets ($70.6M) exceed its short term liabilities ($67.2M).
Long Term Liabilities: AY20's short term assets ($70.6M) exceed its long term liabilities ($28.5M).
Debt to Equity History and Analysis
Debt Level: AY20's net debt to equity ratio (5.3%) is considered satisfactory.
Reducing Debt: AY20's debt to equity ratio has increased from 0% to 47.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AY20 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AY20 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.3% each year